Herbal Formula Effects Transferred Via Fecal Transplant

An Herbal Formula’s Cardiopsychiatric Effects Are Transferable Via Fecal Transplant

Researchers at Zhejiang Chinese Medical University identified a direct, causal link between an herbal treatment, specific gut bacteria, and improvements in both heart function and depression. Their 2026 study, published in Phytomedicine, found the benefits of Huangjin Shuangshen Jiawei decoction were partly mediated through the gut microbiome and could be replicated through fecal microbiota transplantation.

Transplanted Microbes Replicate Herbal Formula’s Dual Benefits

The research team, led by Zhang M and Zhu A, created a mouse model of coronary heart disease with comorbid depression. They treated the animals with Huangjin Shuangshen Jiawei decoction. The treatment significantly improved cardiac function measured by ultrasound, lowered blood markers of heart injury, reduced cell death in heart tissue, and lessened depressive behaviors.

To test if the gut microbiota was essential for these effects, the scientists used a two-part microbial intervention. First, they depleted gut bacteria in a group of mice using broad-spectrum antibiotics. In these germ-depleted mice, the herbal formula’s therapeutic power was “markedly attenuated.” Second, they performed fecal microbiota transplantation. They took stool from mice successfully treated with the herbal formula and transplanted it into sick, untreated mice. The FMT procedure alone was enough to “partially reproduce” the protective effects on both the heart and mood. This transplant experiment provided direct evidence that the formula’s activity depends on its ability to reshape a functional microbial community.

Three Keystone Bacteria Identified as Active Agents

By analyzing stool from human patients with the heart-depression condition who responded to the herbal treatment, the team pinpointed three bacterial species that became enriched: Faecalibacterium prausnitzii, Parabacteroides goldsteinii, and Butyricicoccus pullicaecorum. These are not random bugs; each has documented anti-inflammatory and gut-barrier strengthening properties in other research.

The scientists then conducted a critical validation step. They colonized antibiotic-treated, sick mice with each bacterial strain individually. Each standalone bacterium—whether it was F. prausnitzii, P. goldsteinii, or B. pullicaecorum—produced measurable improvements. Cardiac function got better, heart injury markers dropped, and depressive-like behaviors eased. This proved these specific microbes were not just passive markers of health but active therapeutic agents. The herbal formula likely works, in part, by creating a gut environment that allows these beneficial species to flourish.

A Molecular Pathway Linking Gut Signals to Heart and Brain Cells

The study went beyond observing effects to propose a mechanism. The researchers analyzed heart and brain tissue and found dysregulation in the SRSF1-p53-ASPP1 signaling axis. This pathway is involved in cellular stress responses and programmed cell death. In the disease model, this pathway was overactive, likely contributing to heart cell damage and neural dysfunction.

Treatment with the herbal formula, and separately with the individual beneficial bacteria, helped restore normal regulation of this pathway. This suggests a model where a healthier gut microbiome, enriched with specific anti-inflammatory bacteria, sends molecular signals via the bloodstream or the vagus nerve that calm excessive stress signaling in distant organs. It provides a tangible biological explanation for the gut-heart-brain connection observed in this and other studies on the gut-brain axis in cardiometabolic disease.

Broadening the Scope of FMT and Microbiome-Targeted Therapies

This research has immediate implications for how we view fecal microbiota transplant and microbiome modulation. While FMT is an established treatment for recurrent C. difficile infection, its application is being explored for conditions like IBS. This study positions FMT as a vital research tool to prove if a therapy’s benefits are gut-mediated.

For patients and clinicians, it strengthens the case for a multi-pronged approach to complex, systemic conditions. A therapy—whether herbal, dietary, or pharmaceutical—might achieve its greatest effect by supporting a consortium of beneficial microbes. The identified bacteria, particularly Faecalibacterium prausnitzii, are common targets for prebiotic fibers and some probiotic formulations. Future therapies may involve direct supplementation with these precise strains, an approach supported by research on postbiotics and depression.

A key limitation is that these are preclinical findings in mice. The molecular pathway and bacterial effects require confirmation in human trials. Furthermore, FMT carries regulatory and safety hurdles for widespread use beyond specific infections.

Frequently Asked Questions

Could FMT be used to treat depression or heart disease directly?

This study shows the effects of a healthy microbiome transplanted via FMT can improve symptoms in a model combining both conditions. While promising, FMT is not yet a standard treatment for depression or heart disease alone, and more human clinical research is needed to establish its safety and efficacy for these uses.

Are the three bacteria identified available as probiotics?

Faecalibacterium prausnitzii is a prominent target of prebiotic diets and is the subject of ongoing probiotic development, but it is an anaerobic bacterium that is difficult to commercially formulate. Some probiotic blends aim to support its growth. Parabacteroides goldsteinii and Butyricicoccus pullicaecorum are also under research but are not widely available in consumer supplements today.

Does this mean herbal medicine is better than pharmaceuticals for gut-brain conditions?

No, it means that complex herbal formulations, like some pharmaceuticals, can exert their effects through the microbiome. The study provides a scientific framework for understanding how such treatments work, which could lead to better-designed therapies of all types—herbal, dietary, or synthetic—that target the gut ecosystem.

Sources:
https://pubmed.ncbi.nlm.nih.gov/42542058/
https://pubmed.ncbi.nlm.nih.gov/42538091/
https://pubmed.ncbi.nlm.nih.gov/42538089/